Treatment · United States
Zurzuvae, the first oral postpartum depression treatment, becomes available in the U.S.
The 14-day oral course offers an alternative to the IV-only brexanolone that preceded it.
Biogen and Sage Therapeutics' Zurzuvae (zuranolone) became the first FDA-approved oral medication specifically for postpartum depression when it launched in the U.S. in late 2023. The 14-day, once-daily course is a major practical step forward from brexanolone, which required a 60-hour IV infusion and a certified inpatient setting.
Trial data showed rapid symptom improvement — by Day 15 and as early as Day 3. Open questions remain about cost, insurance coverage, and how the drug fits alongside SSRIs in real-world practice.
Read Biogen's launch release for the dosing and trial details.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.
If reading this brought something up for you —
Call or text 988 for the Suicide & Crisis Lifeline. See all crisis resources.